In contrast to the results obtained in AAV-shFGF9-infected DIO mice, Ad-FGF9 injection improves glucose intolerance as revealed by GTT experiments (Figure 5B), and enhanced insulin sensitivity, as revealed by ITT experiments (Figure 5C), and enhanced hepatic insulin signaling (Figure 5D). Here, INS is linked to Glucose intolerance.